%) (71.70%) (49.90%) Basic earnings per share-Owners of the Company (0.18 ) (0.10 ) (0.08) (76.07%) (0.08%) (0.06%) Attributable to Owners of the Company (155.70) (88.43) (67.27 ) (76.07%) Non-controlling
7.59% 9.73 8.81% EBITDA 150.59 6.40% 140.59 9.66% 10.50 7.47% Finance cost and tax income 0.61 0.03% (0.25) (0.02%) 0.86 (344.00%) Net profit 119.51 5.08% 110.64 7.60% 8.87 8.02% Basic earnings per share
minority interest 7. Profit (Loss) from ordinary activities 8. Extraordinary Items 9. Net income (loss) 10. Earnings per share 10.1 Basic earning per share 10.1.1 Net profit (loss) before extraordinary items
. Net profit (Loss) of minority interest 7. Profit (Loss) from ordinary activities 8. Extraordinary Items 9. Net income (loss) 10. Earnings per share 10.1 Basic earning per share 10.1.1 Net profit (loss
0.94% 576.65 8.97% (503.65) -87.34% Finance cost and tax income 1.61 0.02% (4.54) -0.07% 6.15 135.46% Net profit (22.13) -0.29% 423.62 6.59% (445.75) -105.22% Basic earnings per share (Baht per share
as it was necessary for customer-base expansion in dialysis solution segment to adjust selling price in order to be competitive with competitors in the same market. As a result, 2017 has gross margin
subsidiaries decreased because the Social Security Office have reduced the payment of medical expenses of high-cost deseases from 12,800.- to 10,200.-Baht,so the company has to adjust the revenue that was
will adjust our production strategy to match with the domestic consumption and export the foreseeable in future. We would like to sincerely thank all our shareholders for their support and belief in the
%) 165.58 187.20 (11.55%) Basic earnings per share (Baht per share) 0.0350 0.0914 0.0585 (40.17%) (61.67%) 0.1262 0.1431 (11.81%) Net Profit For 2nd quarter of 2022 ended as of June 30, 2022, the Company and
) 46.08 82.41 (273.28%) (409.90%) 22.79 269.61 (91.55%) Basic earnings per share (Baht per share) (0.1085) 0.0350 0.0630 (272.21%) (409.83%) 0.0174 0.2061 (91.58%) Net Profit For 3rd quarter of 2022 ended